Threshold value of the cost for life-years gained by adopting health technologies in Spain: Evidence from a literature review;Valor umbral del coste por año de vida ganado para recomendar la adopción de tecnologías sanitarias en España: Evidencias procedentes de una revisión de la literatura

Pharmacoeconomics - Spanish Research Articles

Volumn 4, Issue 3, 2007, Pages 97-107

  De Cock, Erwin ^a   Miravitlles, Marc ^b   González Juanatey, José Ramón ^c   Azanza Perea, José Ramón ^d  

^a United BioSource Corporation   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Instituto de Salud Carlos III

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HEALTH CARE SYSTEM; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SANITATION; SPAIN;

EID: 45249113469     PISSN: 1695405X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03320930     Document Type: Article

References (49)

1. Soto J. Nuevos medicamentos en España: ¿Cuándo deberían ser considerados alternatives coste-efectivas e inversiones rentables para el sistema nacional de salud? Farm Hosp 2004;28:296-304.
2. Johannesson, M. Meltzer D. Some Reflections on Cost-Effectiveness Analysis. Health Econom 1998;7:1-7.
3. Laska EM, Meisner M, Siegel C, et al. Ratio-based and net benefit based approaches to health care resource allocation: proofs of optimality and equivalence Health Econom 1999;8:171-174.
4. National Institute for Clinical Excellence. Guide to the Method of Technology Appraisal. 2004 (http://www.nice.org.uk/pdf/TAP_Methods.pdf)
5. Socialstyrelsen (National Board of Health and Welfare). The Swedish National Board of Health and Welfare's Guidelines for Cardiac Care 2004 Support for Decisions in Setting Priorities. Socialstyrelsen, 2004; Available at: http://www.socialstyrelsen.se/Publicerat/2004/8511/2004-102-2.htm
6. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit 2002;16:334-343.
7. Badia X, Bueno H, González Juanatey JR, Valentín V, Rubio M. Análisis de la relación coste-efectividad a corto y largo plazo de clopidogrel añadido a terapia estándar en pacientes con síndrome coronario agudo en España. Rev Esp Cardiol 2005;58:1385-95.
8. OECD Economic Outlook No. 76. Annex Table 18 Consumer price indices. Available at: http://www.oecd.org ; Accessed October 20, 2005.
9. Navas E, Salleras L, Gisbert R, Dominguez A, Timoner E, Ibanez D, Prat A. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain). Vaccine 2005;23:2342-8.
10. Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003;17:687-694.
11. Hart WM, Rubio-Terrés C, Pajuelo F, González Juanatey JR. Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study. Eur J Heart Fail 2002;4:553-8.
12. Cook JR, Yin D, Alemao E, Davies G, Krobot KJ, Veltri E, Lipka L, Badia X. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway. Pharmacoeconomics 2004;22(Suppl 3):49-61.
13. Hart WM, Rubio-Terres C, Pronk L, Kobina S, Diaz Rubio E. Cost-effectiveness analysis of irinotecan plus fluorouracil/folinic acid compared with fluorouracil/folinic acid alone as first-line treatment for advanced colorectal cancer. Rev Oncol 2003;5:517-523.
14. Asensi F, De Jose M, Lorente M, Moraga F, Ciuryla V, Arikian S, Casciano R, Vento M. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value in Health 2004;7:36-51.
15. Latour-Perez J, Navarro-Ruiz A, Ridao-Lopez M, Cervera-Montes M. Using clopidogrel in non-ST-segment elevation acute coronary syndrome patients: a cost-utility analysis in Spain. Value Health 2004;7:52-60.
16. Mar J, Rueda JR, Duran-Cantolla J, Schechter C, Chilcott J. The cost-effectiveness of nCPAP treatment in patients with moderate-to-severe obstructive sleep apnoea. Eur Respir J. 2003;21:515-22.
17. Nuijten MJ, Villar FA, Kosa J, Nadipelli V, Rubio-Terres C, Suarez C. Cost-effectiveness of enoxaparin as thromboprophylaxis in acutely ill medical patients in Spain. Value Health 2003;6:126-36.
18. Buti M, Casado MA, Fosbrook L, Esteban R. Which is the most cost-effective combination therapy strategy using interferon alfa-2b plus ribavirin for naïve patients with chronic hepatitis C? Clin Drug Invest 2002;22:31-39.
19. Gambús G, Espinosa C. Análisis coste-efectividad de fluvastatina en pacientes coronarios teas una intervención coronaria percutánea. Rev Esp Econ Salud 2003;2:327-329.
20. Rubio-Terrés C, Rodríguez J, Bolinder B, Pablos P. Análisis coste-utilidad del tratamiento de la diabetes mellitus con insulina glargina o insulina NPH en España. Rev Esp Econ Salud 2003;2:313-324.
21. Plans P. Cost-effectiveness of 23-valent antipneumococcical vaccination in Catalonia (Spain). Gac Sanit 2002;16:392-400.
22. Soto Álvarez J, González Vilchez F. Análisis coste-efectividad del uso de espironolactona en el tratamiento de la insuficiencia cardiaca crónica. An Med Interna (Madrid) 2001;8:421-425.
23. Brosa Riestra M, Rubio-Terrés C, Nadipelli V, Casado Collado A, Martínez Brotons F. Análisis coste-efectividad de enoxaparina en la profilaxis de la enfermedad tromboembólica venosa en pacientes sometidos a cirugía mayor ortopédica. Farm Hosp 2003;4:210-8.
24. Brosa Riestra M, Crespo Palomo C. Análisis coste-efectividad del manejo protocolizado de la dislipemia mediante atorvastatina versus práctica clínica habituai en la prevención secundaria de enfermedad cardiovascular. Rev Esp Econ Salud 2004;1:50-56.
25. Sacristán JA, Prieto L, Huete T, Artigas A, Badia X, Chinn C, Hudson P. Coste-efectividad de drotrecogina alfa (activada) en el tratamiento de la sepsis grave en España. Gac Sanit 2004;1:50-7.
26. Hart WM, Rubio-Terrés C, Margalet Fernández I, González Juanatey JR. Análisis coste-efectividad del tratamiento con Ramipril de pacientes con alto riesgo de padecer eventos car-diovasculares en España. An Med Interna (Madrid) 2002; 10: 515-520.
27. Plans Rubió P, Tresserras Gaju R, Navas Alcala E, Pardell Alenta H. Estudio de coste-efectividad del tratamiento de la hipertensión arterial en Cataluña. Med Clin (Barc) 2002; 118: 211-6.
28. Moreno A, Vargas E, Soto J, Rejas J. Análisis coste-efectividad del empleo de celecoxib en el tratamiento de la artrosis. Gac Sanit 2003;1:27-36.
29. García Areces MF, Reyes Martín A, Peón Menéndez R, García Losa JL, Herrero de Dios A. Simulación del coste-efectividad de tratamientos hipolipemiantes en la prevención del infarto agudo de miocardio en adultos. Centro de Salud 2002;10:284-288.
30. Hart WM, Rubio Terrés C, Burrell A, Arístegui I, Escobar-Jiménez F. Análisis farmacoeconómico del tratamiento de la osteoporosis postmenopáusica con Risendronato o Alendronato. REEMO 2002;3:97-104.
31. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-481.
32. Plans P, Rovira J. Estudio coste-efectividad de los tratamientos farmacológicos hipolipemiantes. Med Clin (Barc) 1995;105:327-33.
33. Plans Rubio P. Cost-effectiveness of cardiovascular prevention programs in Spain. Int J Technol Assess Health Care 1998;14:320-30.
34. Puig J, Pinto JL, Dalmau E, editors. El valor monetario de la salud. Barcelona: Springer Verlag; 2001.
35. Buti M, Casado MA, Fosbrook L, et al. Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. J Hepatol 2000;33:351-8.
36. Plans-Rubió P. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease. Pharmacoeconomics 1998;13:623-43.
37. Ammet A, Baltussen R, Duru G, Rigaud-Bully C, Graeve D, Ortqvist A, et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis 2000;31:444-50.
38. Goldman L, Gordon DJ, Rifkind BM. Cost and health implications of cholesterol lowering. Circulation 1992; 85:1960-1968.
39. Iníguez A. Prótests intracoronarias (stent): una aproximación al análisis de coste-efectividad. Rev Esp Cardiol 1997;50(supl 2):83-94.
40. Garber AM Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997;16:1-31.
41. Towse A, Pritchard C, Devlin N. Cost-effectiveness thresholds: economic and ethical issues. King's Fund and Office of health Economics, November 2002. BSC Print Ltd, London.
42. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econom 2004;5:437-52.
43. Harris GB, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001;19:1103-9.
44. Graham JD, Corso PS, Morris JM, Segui-Gómez M, Weinstein MC. Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health 1998;19:125-52.
45. Chapman RH, Stone PW, Sandberg EA, Bell C, Newmann PJ. A comprehensive league table of cost-utility ratios and a sub-table of panel-worthy studies. Med Decis Making 2000;20:451-67.
46. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink M, et al. Cost-effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002;346:1800-6.
47. Casparie AF, van Hout BA, Simoons M. Guidelines and costs. Ned Tijdschr Geneeskd 1998;142:2075-7.
48. OECD Health Data 2002: a comparative analysis of 30 countries: 2002 Edition. Información adicional: http://www.oecd-publications.gfi-nb.com/ OECDBookShop.storefront/EN/product (accesibilidad verificada el 10-Mayo-2003).
49. Pinto JL, Rodríguez R. ¿Cuánto vale la pena gastarse para ganar un año de vida ajustado por calidad? Un estudio empírico. En: Puig J, Pinto JL, Dalmau E, editors. El valor monetario de la salud. Barcelona: Springer Verlag; 2001.